Spots Global Cancer Trial Database for A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

Official Title: A Phase 1 Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

Study ID: NCT04200066

Conditions

Glioblastoma

Brain Tumor

Interventions

Temozolomide, Tamoxifen, Maprotiline

Study Description

Brief Summary: The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.

Detailed Description: The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen. Temozolomide is approved to treat glioblastoma and the investigator wants to understand what doses are safe to use. Tamoxifen has been used for many years to treat breast cancer and there have also been studies combining it with temozolomide for the treatment of brain tumors that have shown the combination to be safe. In this study, the investigator will be adding maprotiline to temozolomide and tamoxifen, determining the highest possible dose that is safe, making sure there are no significant drug interactions and studying the safety of this combination.